CI
VRTX icon

Cordant Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Cordant Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23
Closed -$6K – 1221
2022
Q1 		$6K Buy
+23
New +$5.46K ﹤0.01% 233
2020
Q1 		– Sell
-63
Closed -$14K – 188
2019
Q4 		$14K Buy
+63
New +$12.8K 0.01% 71

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cordant Inc's VRTX Position: Q2 2022 in Review

Cordant Inc sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 23 shares — an estimated $6K sold.

Cordant Inc first reported a position in VRTX in Q4 2019 and held it in 2 quarters. The position peaked at $14K in Q4 2019. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Cordant Inc reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cordant Inc sold 23 Vertex Pharmaceuticals shares in Q2 2022, an estimated $6K.
  • Cordant Inc first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Cordant Inc's Vertex Pharmaceuticals position peaked at $14K in Q4 2019.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.